RedHill Biopharma Ltd. (TASE: RDHL)reported that the United States Patent and Trademark Office has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/918,310 entitled
“Methods and Compositions for Treating Inflammatory Bowel Disease”, directed to
RedHill’s RHB-104 indicated for the treatment of Crohn’s disease.
The company is in preparations for a Phase III clinical trial in the US, Canada and Israel with RHB-104 to treat Crohn’s disease, currently scheduled to commence during the first half of 2013. In addition, the company is in preparations for a Phase IIa scheduled to commence in January, 2013, to assess the efficacy and safety of RHB-104 as an add-on therapy for the treatment of Multiple Sclerosis.
The company’s current product pipeline includes a once-daily formulation of a leading congestive heart failure and high blood pressure drug, a once-daily formulation of a leading radiotherapy-induced nausea and vomiting prevention drug, an oral